Future of UK Health Funding in a New US Deal

A fresh agreement between Britain and the United States has raised alarms about how much money will be pulled from England’s public health system.
The deal, signed in December, requires the UK to double its budget share for new medicines—from 0.3 % of GDP to at least 0.6 %—to avoid potential trade tariffs from the U.S. The UK government hopes this will keep drugs and medical devices flowing freely between the two countries for three years.

Experts from York, Liverpool and Christchurch warn
This extra spending will cost the National Health Service (NHS) an estimated £45 billion by 2036. In a world where budgets are fixed, spending more in one area means less money is available for others. The analysis warns that without additional funding from the government, diverting resources to new medicines could lead to nearly 230 000 more deaths in England over the next decade.

The most vulnerable groups—people with heart disease, lung problems, digestive illnesses and cancer—are expected to bear the brunt of these losses. The study also points out that Britain is still a net importer of medicines, so much of the extra money may go to multinational companies rather than staying in the local economy.

While officials have praised the deal as a “landmark” that protects medicine access and boosts investment, critics argue that it is based on a mistaken belief that avoiding U.S. tariffs will automatically bring economic gains to the UK. By 2031, the projected cost of the deal could exceed the total value of British pharmaceutical exports to America.

Official stance
The Department for Health and Social Care, along with the Department for Business and Trade, has not yet responded to requests for comment. The debate continues over whether the promised benefits outweigh the potential health costs.